Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFN1213
- Development stage
- Phase 1
- Lead developer
- Hefei Afana Biotechnology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AFN1213 is an mRNA-based vaccine candidate developed by Hefei Alphana Biotech for the prevention of herpes zoster (shingles). The vaccine utilizes messenger RNA technology to encode a specific antigen of the varicella-zoster virus (VZV), typically the glycoprotein E (gE), to elicit a robust protective immune response. It is currently being evaluated in Phase 1 clinical trials in China, specifically targeting adults aged 40 years and older. The clinical evaluation focuses on the safety, tolerability, and preliminary immunogenicity of a two-dose regimen administered intramuscularly at months 0 and 2.
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on AFN1213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFN1213.